Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-1284 adjunctive treatment for generalized anxiety disorder with inadequate response to current therapy
2024-513302-56-00Phase 2Authorised
- Sponsor
- Intra-Cellular Therapies
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing ITI-1284 adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: Change from baseline to Week 6 in HAM-A total score. Planned start Mar 2025; status: authorised.
02
Drugs
deulumateperone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2024-513302-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513302-56-00.